[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100526619":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":26,"collaborators":30,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":10,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":42,"enrollmentInfo":43,"targetDuration":10,"studyType":46,"phases":10,"briefSummary":47,"conditions":48,"keywords":10,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":10},{"fullName":5,"class":6},"Assiut University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1",null,"Group I : Romiplostim and Eltrombopag",[13],"Drug: eltrombopag and romiplastim",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 2","Group II : recived corticosteroid.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","eltrombopag and romiplastim","Group I: eltrombopag and romiplastim\n\nGroup II : recived corticosteroid.",[9,15],[25],"Corticosteroids",{"type":27,"investigatorFullName":28,"investigatorTitle":29,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Naira Ibrahem Ahmed Saad","A Study of Treatment with thrombopoietin agonists in patients with Idiopathic thrombocytopenic purpura",[31],{"name":32,"class":6},"Association for Training, Education, and Research in Hematology, Immunology, and Transplantation","100526619","thrombopoietin-agonists-in-patients-with-idiopathic-thrombocytopenic-purpura-100526619",false,"NCT06137105","Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura","A Study of Treatment With Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura","Inclusion Criteria:\n\n* Patients presented with Idiopathic thrombocytopenic purpura (ITP)\n\n  1. patients above age of 18 years.\n\nExclusion Criteria:\n\n* patients below age of 18 years .","ALL","18 Years","75 Years",{"count":44,"type":45},100,"ESTIMATED","OBSERVATIONAL","1. Assesement of response to Thrombopoietin receptor agonists (TPO-RAs) as treatment in Idiopathic thrombocytopenia purpura patients in Assiut University hospital.\n2. Explore side effects of Thrombopoietin receptor agonists in Idiopathic thrombocytopenia purpura .\n3. To study effect of thrombopoietin receptor agonists and Quality life in Idiopathic thrombocytopenia purpura patients.",[49],"ITP - Immune Thrombocytopenia","NOT_YET_RECRUITING","2023-11-16",{"date":53,"type":54},"2023-11-18","ACTUAL",{"date":56,"type":45},"2023-12-01",{"date":58,"type":45},"2026-12",{"name":5,"class":6}]